MTKP 97-12 (ATCC® CRL-8985)

Organism: Mus musculus, mouse  /  Cell Type:: Melanoma  /  Tissue: subcutaneous connective tissue; areolar and adipose  /  Disease: normal

Organism Mus musculus, mouse
Tissue subcutaneous connective tissue; areolar and adipose
Cell Type Melanoma
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease normal
Age 100 days
Gender male
Strain C3H/An
Applications
produces protein antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
The MTKP 97-12 cell line was produced by transfecting LMTK- cells with the expression plasmid pMTp97b that contains a cDNA sequence coding for the p97 melanoma associated antigen.
Clinical Data
male
Genes Expressed
antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 [MFI2],antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5
Comments
The insert contains the following restriction sites (approximate kb from the 5' end): BamHI--1.3, 2.6; HindIII--2.7; PvuII--0.6, 1.6; SstI--0.4, 1.7, 2.3; SalI--1.3.
The MTKP 97-12 cell line was produced by transfecting LMTK- cells with the expression plasmid pMTp97b that contains a cDNA sequence coding for the p97 melanoma associated antigen.
The cells produce approximately 4,000,000 molecules of p97 per cell under the control of the mouse metallothionein promoter.
A metallothionein promoter has been added upstream of the cDNA sequence. Expression can be induced by treating with 80 uM ZnCl and 9 uM CdCl for 24 hrs.
Digestion with EcoRI and HindIII excises the insert in two fragments. The larger fragment contains the complete coding sequence, that extends approximately from nt 60 to nt 2300.
Complete Growth Medium Dulbecco's modified Eagle's medium, 85%; fetal bovine serum, 15%
Subculturing
Medium Renewal: Twice per week
Remove old medium, add fresh 0.25% trypsin, EDTA (0.02%) solution, rinse and remove. Allow cells to sit at room temperature (or at 37C) until cells detach (approximately 10 minutes). Add fresh medium, aspirate and dispense into new flasks.
Cryopreservation
culture medium, 50%; fetal bovine serum, 40%; DMSO, 10%
Name of Depositor Oncogen
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Brown JP, et al. Vaccines against melanoma. US Patent 5,141,742 dated Aug 25 1992

Brian W Poor, personal communication

Basic Documentation
References

Brown JP, et al. Vaccines against melanoma. US Patent 5,141,742 dated Aug 25 1992

Brian W Poor, personal communication